In RA-ILD, retrospective cohort studies of IL-6 receptor inhibitors such as tocilizumab and sarilumab have suggested that IL-6/STAT3 blockade can control synovial inflammation without worsening ILD [201,202], although robust controlled data are limited. Here, STAT3 is linked to interstitial lung disease.